
Abstract Tumor‐associated macrophages (TAMs) as the most abundant and dominant immune cells in the tumor microenvironment (TME) exhibit pronounced phenotypic plasticity and a typical Janus role in both tumor suppression and promotion. In most solid tumors, TAMs predominantly differentiate into an M2‐like phenotype, which suppresses adaptive immunity and promotes tumor metastasis. It is closely related to the therapeutic resistance and poor patient prognosis. Recently, targeted TAM modulation, which is focused on the reprogramming of TAMs toward a pro‐inflammatory, antitumor M1 phenotype, has emerged as an extremely promising immunotherapeutic strategy. However, the therapeutic efficacy of current pharmacological approaches remains suboptimal, owing to their insufficient tumor specificity, dose‐limiting systemic toxicity, poor intratumoral drug delivery, as well as inherent instability and reversibility of reprogrammed macrophage phenotypes within the persistently immunosuppressive TME. Fortunately, nanoparticle‐based immune agonists have provided versatile platforms with selective targeting, spatiotemporal control, and prolonged immunomodulatory effects, offering a promising strategy to precisely reprogram TAM phenotypes. This review systematically summarizes the molecular mechanisms associated with TAM polarization, and particularly focuses on the major regulatory pathways including nuclear factor‐κB (NF‐κB), Janus kinase signal transducer and activator of transcription (JAK‐STAT), cyclic GMP‐AMP synthase‐stimulator of interferon genes (cGAS‐STING), mitogen‐activated protein kinase (MAPK), metabolic reprogramming, and their coordinated interactions. It further provides a comprehensive overview of recent advances in nanoagonist‐based strategies that intervene in these pathways to reprogram TAMs, critically discussing their therapeutic potential, current limitations, and translational prospects. Collectively, this work provides an integrated mechanistic and technological framework to guide the rational design of macrophage‐targeted nanomedicine for tumor immunotherapy.
Abstract The failure of meniscal implants often stems from their inability to replicate the dynamic mechanical adaptability of the native tissue, leading to stress imbalances and irreversible joint degeneration. Current scaffolds, designed for static structural mimicry, fail to reproduce the crucial “compression‐to‐tension” conversion mechanism, resulting in high failure rates and accelerated osteoarthritis. Here, we report a paradigm shift from static mimicry to dynamic functional replication by engineering a biomimetic textile‐based meniscal scaffold (AN‐3DWKS). Our approach utilizes a textile micro‐forming strategy to construct a three‐dimensional anisotropic fiber‐interlocked skeleton, which is then integrated with a mechanically optimized annealed hydrogel. This composite scaffold exhibits a native‐like biphasic mechanical response: it is compliant under low strain for stress buffering but stiffens under high strain, converting axial loads into circumferential tension with a load‐bearing capacity exceeding 2400 N. Finite element analysis reveals this behavior is driven by the synergistic interplay between the hydrogel matrix and the sequential engagement of the fiber network. In a 24‐week rabbit model of total meniscectomy, the AN‐3DWKS restored joint mechanical homeostasis, maintained cartilage integrity at levels statistically comparable to those in the sham group, and suppressed inflammatory markers (TNF‐α). This work establishes a new design principle for load‐bearing soft tissues, demonstrating that emulating dynamic physiological responsiveness is the key to long‐term functional restoration and osteoarthritis prevention.
Abstract Stiffness is a key mechanical cue of the extracellular matrix (ECM) and biomaterials in tissue engineering. It plays a pivotal role in regulating cellular behaviors and determining cell fate through specific mechanotransduction pathways, including integrin‐mediated signaling and cytoskeletal dynamics. Biomaterials with tunable stiffness in both two‐dimensional (2D) and three‐dimensional (3D) formats have been developed to investigate the influence of stiffness on tissue regeneration. This is particularly relevant in the motor system, where tissue stiffness spans a broad range and mechanical cues are crucial. In this review, we first highlight the multiple roles of matrix stiffness in biological processes, from guiding tissue development and maintaining homeostasis to regulating cell behaviors. We then summarize the design and fabrication strategies for tunable‐stiffness biomaterials in both 2D and 3D formats. Finally, we discuss the functional applications of these biomaterials in the motor system and their potential applications in regenerative medicine.
Abstract Extracellular vesicles (EVs) are double‐membrane vesicular structures that can be secreted by nearly all living cells. These vesicles serve as “carriers” enabling the intercellular transport of membrane‐bound and soluble proteins, lipids, and RNA. Hence, EVs mediate the transfer of bioactive substances between different cells, playing a crucial role in intercellular communication. In particular, plant‐derived EVs (P‐EVs) have garnered significant attention in recent years due to their wide availability, excellent biocompatibility, inherent stability, low immunogenicity, and non‐toxicity. The potential of P‐EVs as natural therapeutic agents and drug delivery vehicles has been increasingly recognized, offering promising therapeutic avenues for various diseases. In this article, we first discuss the nomenclature of P‐EVs. We then review current strategies for their isolation and characterization as well as properties and biosafety profiles. Given the unique morphology and rich content of bioactive molecules present in these natural nanocarriers, we also summarize recent advances in the engineering and functional modification of P‐EVs, their application as delivery vehicles, and their therapeutic effects in disease models. Furthermore, we review the latest developments in patents and clinical research related to P‐EVs. Finally, we highlight the current limitations and challenges hindering the clinical translation of P‐EVs, including the need for improved isolation and purification methods, comprehensive physicochemical assessments, stringent quality control, safety assessments, delivery route optimization, and in‐depth pharmacodynamic and mechanistic analyses. We hope that this review will provide reference points and guidance for researchers in this field, thereby promoting further advances in P‐EVs research.
Abstract Age‐related bone disorders, such as osteoporosis (OP) and osteoarthritis (OA), are commonly associated with bone loss, cartilage degeneration, and impaired joint function, creating a significant health burden. Bone and cartilage organoids have become promising 3D models because they can partially reproduce natural tissue structures, cell diversity, and extracellular matrix features. However, current organoid systems still rely on biomaterial scaffolds and growth factors, which limits their ability to model multicellular crosstalk. Bacterial extracellular vesicles (BEVs) are non‐replicative nanoscale vesicles released by bacteria and enriched with diverse bioactive molecules. Compared with mammalian EVs or recombinant growth factors, BEVs are attractive because they are genetically programmable, scalable, and low cost. In this review, we discuss how BEVs can be integrated with bone and cartilage organoids, focusing particularly on the biological mechanisms, engineering methods, translational applications, biosafety issues, standardization requirements, and delivery challenges of BEVs. BEVs‐enabled organoids may provide programmable and scalable platforms for skeletal disease modeling, patient‐specific drug screening, and regenerative therapy.